UBX-303061

N/A

Report date: 2024/12/23 11:59:12
NME

Base Information

Drug NameUBX-303061
Drug Alias NameUBX-303061
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUbix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUbix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A